MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2022 International Congress

September 15-18, 2022. Madrid, Spain.

View by Title View Categories
Jump to:  View All • [a] b c d e f g h i j k l m n o p q r s t u v w x y z
  • A 69-year-old man with seizure-like activity and unresponsiveness

    J. Patino, A. Durand, R. Samudralwar (Houston, USA)

  • A bitter syndrome as a cause of refractory movement disorders

    DD. García-Meléndez, F. Muñoz Escudero, MI. Morales-Casado, P. Lobato Casado, AM. Diezma Martín, G. Tabar Comellas, N. Sánchez Cano, B. Canovas Gaillemin, N. López Ariztegui (Toledo, Spain)

  • A brainstem-oriented PET/NMR method in Parkinson’s disease

    Q. Demonceau, G. Demonceau, V. Lebon (Orsay, France)

  • A case of levodopa responsive parkinsonism due to methanol toxicity, an impact of COVID-19 crisis

    M. Shah, L. Patil, M. Bhatt (Mumbai, India)

  • A CASE OF MEIGE SYNDROME IN INDONESIA TREATED WITH HALOPERIDOL

    K. Kandhisa, EA. Albertin, MG. Gaharu (Jakarta, Indonesia)

  • A Case of Neurodegeneration with Brain Iron Accumulation with novel Adaptor Protein-4 M1 subunit mutation

    A. Battineni, D. Vijayakumar (Greenville, USA)

  • A CASE REPORT OF EARLY-ONSET SPINOCEREBELLAR ATAXIA TYPE 35

    I. Delpino Delaguno, C. Derojas Leal, O. León Plaza, MJ. Gómez Heredia, F. Pérez Errazquin (Málaga, Spain)

  • A Case Series of children with Choreo-athetoid movements diagnosed with Anti-N-Methyl-D-Aspartate Receptor Encephalitis

    RP. Vasireddy, ZG. Guduru, QK. Khan (Lexington, USA)

  • A Case series of Hemichorea Hemiballism Associated with Non-ketotic Hyperglycemia and Unique Imaging findings

    RP. Vasireddy, M. Thandampallayam, Z. Guduru (Lexington, USA)

  • A case with clinical features of alpha-synuclein- and tauopathy: Genetic and histopathological workup.

    D. Gruber, C. Mawrin, A. Vogel, T. Usnich, N. Brueggemann, C. Klein, P. Bauer, F. Gandor, G. Ebersbach (Beelitz-Heilstaetten, Germany)

  • A child with infantile onset paroxysmal episodes of jerks and stiff limbs

    A. Das, A. Elavarasi, R. Singh, D. Vibha, M. Tripathi (Delhi, India)

  • A clinico-genetic study based on the Innsbruck MSA Registry

    F. Leys, S. Eschlboeck, N. Campese, P. Mahlknecht, M. Peball, V. Sidoroff, R. Granata, V. Bonifati, J. Zschocke, S. Kiechl, W. Poewe, K. Seppi, GK. Wenning, A. Fanciulli (Innsbruck, Austria)

  • A dose-response study of the effect of the mGlu2/3 orthosteric antagonist LY-341,495 on the anti-dyskinetic and anti-psychotic effect of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset

    S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

  • A double-blind randomized clinical trial to evaluate the effects of Candesartan for Cognitive and Neuropsychiatric Impairment in Parkinson’s Disease

    J. Kulisevsky, S. Martinez-Horta, A. Campolongo, B. Pascual-Sedano, J. Marin-Lahoz, H. Bejr-Kasem, A. Puig-Davi, J. Pagonabarraga, J. Rodriguez-Antiguedad (Barcelona, Spain)

  • A facilitated self-management toolkit for people with Parkinson’s disease: A feasibility study of ‘Live Well with Parkinson’s

    M. Armstrong, T. Rookes, A. Schrag, K. Walters (London, United Kingdom)

  • A fully immersive virtual reality environment to study gait modulation in Parkinson’s disease

    I. Hanafi, P. Kullmann, IU. Isaias, C. Palmisano (Würzburg, Germany)

  • A Literature Review: Effectiveness of Transcranial Direct Current Stimulation on gait speed and freezing of gait in patients with Parkinson’s disease

    T. Mok (hong kong, Hong Kong)

  • A longitudinal evaluation of the peripheral immune phenotype in a cohort of Parkinson’s disease patients

    L. Magistrelli, A. Furgiuele, E. Contaldi, M. Legnaro, E. Rasini, C. Comi, F. Marino, M. Cosentino (Novara, Italy)

  • A low-cost system using a big-data deep-learning framework for assessing physical tele-rehabilitation: a proof-of-concept

    A. Olivares-Gil, JM. Ramírez-Sanz, JL. Garrido-Labrador, á. García-Bustillo, á. Arnaiz-González, JF. Díez-Pastor, J. González-Santos, JJ. González-Bernal, M. Allende-Río, F. Valiñas-Sieiro, JM. Trejo-Gabriel-Galan, E. Cubo (Burgos, Spain)

  • A lower rate of hyposmia in non-Ashkenazi jewish patients with Parkinson’s disease: motor and non-motor disease characteristics in different ethnic groups in Israel

    ME. Cohen, E. Kohn, R. Valdman, R. Eichel, G. Yahalom (Jerusalem, Israel)

  • A Man Who Has Been Presenting with Pruritus and Myoclonus

    EJ. Choi, DG. Lee, AR. Lim (Gumi, Republic of Korea)

  • A Mixed Methods Study on the Impact of Reading the Graphic Memoir My Degeneration: A Journey Through Parkinson’s on Patients with Parkinson’s Disease

    M. Green, S. de Jesus, D. George, L. van Scoy, K. Myers (Hershey, USA)

  • A modified Delphi panel to establish a threshold of meaningful progression on MDS-UPDRS Part III

    D. Trundell, L. Barrett, R. Rogers, E. Davies, S. Zanigni, N. Pross, G. Pagano, T. Nikolcheva, S. Cano (Welwyn Garden City, United Kingdom)

  • A motor-cognitive intervention impacts daily-living gait and activity in Parkinson’s disease fallers differently than a motor intervention: analysis using a machine learning approach

    K. Cohavi, S. Del Din, E. Gazit, E. Pelosin, L. Avanzino, N. Nieuwboer, B. Bloem, A. Cereatti, U. Croce, L. Rochester, N. Giladi, J. Hausdorff, A. Mirelman (Tel Aviv Yafo, Israel)

  • A mouse model to test the cortical pathogenic theory of Parkinson’s disease

    M. Moreno-Gómez, D. Humanes-Valera, J. Pardo-Valencia, N. Mercado-García, B. Pro-Sánchez, A. Revuelto-González, T. Balzano, J. Blesa, A. Bortolozzi, J A. Obeso, G. Foffani (Móstoles, Spain)

  • A Narrative Review of Literature on Exercise Therapy and Cognitive Impairment in Individuals with Parkinson’s Disease: The Role of Epigenetics as a Mediator.

    T. Adeniji, S. Olsen, N. Signal, J. Adeleke (Akoda-Ede, Nigeria)

  • A novel alpha-synuclein gene (SNCA) missense variant in an Austrian familiy with atypical neuropathological features

    C. Brücke, M. Zech, T. Outeiro, E. Gelpi, A. Zimprich (VIenna, Austria)

  • A novel compound heterozygous PANK2 gene mutation in a South- Asian sexagenarian with atypical PKAN

    K. Pillai, B. Maramattom, S. Grover, A. Kishore (Kochi, India)

  • A Novel Mutation of GCH1 Gene in a Case of Dopa-responsive Dystonia with Oculogyric Crises

    T. Kim, D. Yoo, TB. Ahn (Seoul, Republic of Korea)

  • A Novel Parkinson Shoe: A potential treatment of Unresponsive Freezing of Gait in Parkinson’s Disease Patients

    W. Phuenpathom, P. Panyakaew, R. Bhidayasiri (Bangkok, Thailand)

  • A novel platform for home-based, remotely supervised, transcranial direct current stimulation treatment and assessment for Cerebellar ataxia: A randomized, double-blind, sham-controlled, crossover, feasibility study

    N. Inbar, M. Abo-Said, P. Ponger, S. Frenkel-Toledo, M. Brozgol, Z. Hausdorff, Z. Yekutieli, D. Gershman, A. Hilel, A. Ezra, S. Springer, T. Gurevich (Tel Aviv, Israel)

  • A novel RFC1 repeat motif (ACGGG) in a patient with cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS)

    M. Thomsen, M. Borsche, F. Hinrichs, C. Helmchen, N. Brueggemann, K. Lohmann (Luebeck, Germany)

  • A One-year follow-up study of effects of voltage/frequency Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) adjustments on speech intelligibility in Parkinson’s Disease (PD)

    N. Castillo-Triana, M. Camargo-Mendoza, O. Bernal-Pacheco (Bogotá, Colombia)

  • A patient with childhood-onset hearing loss and adult-onset ataxia was genetically diagnosed with Perrault syndrome 5

    J. Park, J. Seok (Cheonan, Republic of Korea)

  • A Patient-Centered Outcomes Survey in Parkinson’s Disease: Results of Cognitive Pre-Testing

    D. Shah-Zamora, J. Karl, M. Tosin, G. Pal, G. Stebbins, C. Goetz, L. Verhagen (Chicago, USA)

  • A Phase 1b study to test the safety, pharmacokinetics, and pharmacodynamics of a novel inflammasome inhibitor in early-stage Parkinson’s disease: Rationale and study design

    G. D'Urso, A. Thomann, J. Anzures-Cabrera, B. Zinnhardt, B. Ricci, M. Marchesi, V. Machado, E. Mracsko, N. Pavese, K. Marek, K. Brockmann, T. Simuni, N. Milani Muelhardt, G. Pagano (Basel, Switzerland)

  • A Phase 2 Clinical Trial Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of PRAX-944 in Adults with Essential Tremor

    O. Olhaye, G. Belfort, S. Raines, T. Snyder, B. Ravina (Boston, USA)

  • A Phase 2 Randomized, Double-blind, Placebo-controlled Trial of PRAX-944 for the Treatment of Essential Tremor

    O. Olhaye, G. Belfort, S. Raines, T. Snyder, B. Ravina (Boston, USA)

  • A phase 2b, randomized, dose-response study of SAGE-324/BIIB124 for the treatment of essential tremor: KINETIC 2 trial in progress

    R. Pahwa, A. Ellenbogen, R. Elble, K. Bankole, T. Dam, J. Fratantonio, J. Gaiha-Rohrbach, M. Qin, S. Garafola, M. Gerbasi, H. Colquhoun (Kansas City, USA)

  • A Pilot Feasibility Study of Medium Chain Triglyceride Nutritional Ketosis and Parkinson’s Disease

    A. Choi, M. Delgado, K. Chen, S. Chung, A. Courville, S. Turner, S. Yang, K. Airaghi, I. Dustin, P. Mcgurrin, M. Hallett, D. Ehrlich (Sun City, USA)

  • A Potential Cluster Near Site of Dry Cleaning Contamination

    M. Pawlik, S. Lettenberger, M. Zafar, M. Coffey, A. Sarkar, P. Auinger, C. Tanner, S. Goldman, B. de Miranda, K. Kieburtz, R. Barbano, M. Braun, H. Schwarz, D. Kinel, R. Dorsey (Rochester, USA)

  • A precompetitive consortium approach to designing a qualitative study to generate content validity evidence to support the use of digital health technologies among people with early Parkinson’s disease

    R. Speck, J. Mammen, P. Yang, S. Jensen-Roberts, M. Kostrzebski, R. Dorsey, M. Müller, J. Cosman, J. Hellsten, J. Crawford, G. Stebbins, J. Cedarbaum, T. Simuni, T. Dam, K. Ward Barowicz, D. Stephenson, J. Adams (Tucson, USA)

  • A progress update on the Critical Path for Parkinson’s consortium’s pre-competitive 3DT initiative

    M. Müller, J. Cosman, J. Adams, R. Badawy, R. Bhatnagar, B. Bloem, C. Carroll, N. Cooray, T. Dam, D. Dexter, M. Dockendorf, R. Dorsey, M. Frasier, L. Garcia-Gancedo, D. Hill, M. Kostrzebski, E. Kunka, M. Lindemann, J. Mammen, M. Meinders, A. Mirelman, G. Roussos, S. Sardar, T. Simuni, R. Speck, G. Stebbins, K. Ward Barowicz, J. Cedarbaum, D. Stephenson (Tucson, USA)

  • A PROSPECTIVE COHORT STUDY OF COGNITIVE IMPAIRMENT AND CORTISOL LEVELS IN PARKINSON’S DISEASE

    N. Soares, G. Pereira, A. Dutra, N. Artigas, J. Krimberg, B. Monticelli, A. Schumacher-Schuh, R. de Almeida, C. Rieder (Porto Alegre, Brazil)

  • A prospective, controlled study of subthalamic stimulation in Parkinson’s disease: quality of life outcome at the 5-year follow-up

    S. Jost, S. Aloui, A. Rizos, K. Ashkan, J. Evans, A. Sauerbier, J. Petry-Schmelzer, A. Gronostay, G. Fink, M. Barbe, V. Visser-Vandewalle, A. Antonini, M. Silverdale, P. Martinez-Martin, L. Timmermann, K. Ray Chaudhuri, H. Dafsari (Cologne, Germany)

  • A qualitative study exploring the treatment burden and capacity of people with Parkinson’s and their caregivers

    QY. Tan, H. Roberts, S. Fraser, K. Ibrahim (Southampton, United Kingdom)

  • A randomized clinical trial (RCT) to evaluate the effects of safinamide on apathetic non-demented Parkinson’s disease patients

    J. Kulisevsky, S. Martinez-Horta, A. Campolongo, B. Pascual-Sedano, J. Marin-Lahoz, H. Bejr-Kasem, A. Horta-Barba, A. Puig-Davi, J. Pagonabarraga, I. Aracil-Bolaños, J. Rodriguez-Antiguedad (Barcelona, Spain)

  • A randomized controlled trial comparing the efficacy and safety of pyridostigmine versus midodrine for the treatment of orthostatic hypotension in Parkinson’s disease patients

    C. Limwatthana (Bangkok, Thailand)

  • A randomized, double-blinded crossover trial of short versus conventional pulse width subthalamic deep brain stimulation in Parkinson’s Disease

    JN. Petry-Schmelzer, L. Schwarz, H. Jergas, P. Reker, J. Steffen, H. Dafsari, J. Baldermann, G. Fink, V. Visser-Vandewalle, T. Dembek, M. Barbe (Cologne, Germany)

  • A randomized, sham-controlled, crossover trial on Transcranial pulsed current stimulation (tPCS) in Huntington disease

    M. Tuesta Bernaola, Y. Tamilselvam, Y. Mahdi, J. Ganguly, D. Aur, M. Jog (London, Canada)

  • A Randomized, Wait-List Controlled Trial of the Feasibility and Efficacy of Small Group Online-based Cognitive Behavioral Therapy for Anxiety in Parkinson’s Disease

    N. Nishikawa, T. Hatano, C. Uchida, Y. Ouji, N. Miyamoto, G. Oyama, N. Hattori (Tokyo, Japan)

  • A rare case of Hyperkinetic Movement disorder

    P. A, T. K, S. S, C. P, P. Peter (SALEM, India)

  • A Report from Japan on Initial Experiences with Adaptive Deep Brain Stimulation Therapy for Patients with Advanced Parkinson’s Disease

    N. Tani, S. Oshino, K. Hosomi, H. Khoo, Y. Fujita, T. Emura, S. Miura, Y. Kimotto, T. Matsuhashi, X. He, A. Reza, T. Yanagisawa, H. Kishima (Suita, Japan)

  • A Retrospective Case Review of Movement Disorder Video Case Conference ~ A 20-year Collaboration Between The Queen’s Medical Center in Hawai`i and University of Virginia

    M. Bruno, F. Wooten, M. Harrison, J. Liu, F. Gao, B. Shah, J. Del Castillo, A. Mauro (Honolulu, USA)

  • A role of β2-adrenoreceptor agonist related to the development of Parkinson’s disease

    WW. Lee (Seoul, Republic of Korea)

  • A Scoping Review of Multidisciplinary Care in Tourette Syndrome

    S. Willford, W. Deeb (Worcester, USA)

  • A second level neuropsychological battery for Parkinson’s Disease. Normative data from the Italian population.

    T. Gandolfi, G. Arcara, S. Cuoco, C. Siri, L. Weis, E. Reali, M. Garon, F. Pistonesi, V. Cianci, E. Fiorenzato, G. Santangelo, G. Pezzoli, P. Barone, A. Antonini, R. Biundo (Padova, Italy)

  • A secretory vesicle failure in Parkinson’s disease occurs in human platelets

    P. Montenegro, M. Pueyo, JN. Lorenzo, R. González-Brito, A. Méndez, R. Borges (La Laguna, Spain)

  • A Single-Centre Canadian Study of Disparities in Access to Deep Brain Stimulation for Movement Disorders

    S. Poonja, K. Yen, J. Miyasaki, A. Shetty, T. Sankar, F. Ba (Edmonton, Canada)

  • A Study of Battery Replacement Characteristics of Patients with Parkinson’s Disease and Factors Influencing Battery Drain

    P. Sharma, P. Pal, D. Srinivas, N. Kamble, R. Yadav, V. Holla (Bangalore, India)

  • A STUDY OF CLINICAL SPECTRUM, RISK FACTORS AND OUTCOME OF DRUG-INDUCED MOVEMENT DISORDERS

    R. Anand, S. Pandey, HS. Malhotra, RK. Garg, N. Kumar, R. Uniyal, I. Rizvi (Lucknow, India)

  • A systematic review of Movement Disorders in COVID-19

    K. Pillai, S. Mishra, G. Siripurapu, A. Aliyar, R. Rajan, A. Srivastava, D. Radhakrishnan (Kochi, India)

  • A systematic review of non-motor symptoms in atypical parkinsonian syndromes

    P. Ananthavarathan, B. Patel, R. Lamb, S. Peroos, N. Malek (London, United Kingdom)

  • A systematic review on physical health education interventions for people with Parkinson’s: content, impact and implementation considerations across Parkinson’s trajectory

    L. Alushi, J. Alexander, J. Jones (Cambridge, United Kingdom)

  • A systematic review to compare the effect of bilateral deep brain stimulation (STN versus GPI) on gait and balance in Parkinson’s disease

    D. Dash, D. Vibha, T. Mestre (Ottawa, Canada)

  • A trail towards understanding cognitive impairment in PSP

    S. Kannenberg, A. Hausmann, C. Hartmann, J. Caspers, A. Schnitzler (Duesseldorf, Germany)

  • A Useful Cognitive-Motor Dual Task Paradigm in Prodromal and Manifest HD

    EG. Churchill, J. Corey-Bloom, A. Hall, C. Snell, A. Smirnova, SB. Hughes, PE. Gilbert, DJ. Goble (San Diego, USA)

  • A user experience evaluation of a Huntington’s disease app: Implications for mobile-first design

    E. Wagner, E. Waddell, E. Dorsey, J. Adams (Rochester, USA)

  • A Week in the Life with Parkinson’s Disease: A Holistic Overview from Four Digital Technologies

    E. Hartman, K. Dinesh, M. Pawlik, S. Jensen-Roberts, E. Waddell, T. Myers, J. Soto, E. Nnadika, P. Yang, G. Sharma, M. Islam, A. Abdelkader, W. Rahman, V. Antony, E. Hoque, G. Zhang, Y. Liu, D. Katabi, R. Wilson, K. Lizarraga, C. Tarolli, R. Schneider, E. Dorsey, J. Adams (Rochester, USA)

  • Aberrant visual-related networks in familial cortical myoclonic tremor with epilepsy

    H. Wang, B. Wang, Z. Cen, J. Wang, Y. Zang, D. Yang, Y. Ding, S. Wang, S. Wu, W. Luo (Hangzhou, China)

  • Aberrant Volume-wise and Voxel-wise Concordance among Dynamic Intrinsic Brain Activity Indices in Parkinson’s Disease

    T. Yuan, L. Kai, S. Wen (Beijing, China)

  • Abnormal fractional anisotropy of the tremor network in tremor dominant Parkinson’s disease and Essential tremor plus syndrome

    P. Pal, S. Prasad, R. Bharath, J. Saini (Bangalore, India)

  • Abnormal streamline density of the tremor network in tremor dominant Parkinson’s disease and Essential tremor plus syndrome

    S. Prasad, J. Saini, R. Bharath, P. Pal (Bangalore, India)

  • Absence of nigrosome as a finding in a patient with suspected atypical parkinsonism.

    L. Caballero Sánchez, D. Cerdán Santacruz, C. Gómez López, J. Berrío Suaza, P. Gil Armada, M. álvarez Eulate, A. Castrillo Sanz, A. Mendoza Rodriguez, M. Rodríguez Sanz, C. Tabernero García (Segovia, Spain)

  • Action verb use in PD: A challenge to the embodied cognition hypothesis?

    E. Nascimento Andrade, C. Manxhari, K. Smith (Worcester, USA)

  • Activity and sleep associated with changes in glymphatic imaging-markers in Parkinson Disease patients enrolled in 3-month exercise program

    J. Elenberger, J. Eisma, K. Hett, A. Song, C. Mcknight, Y. Yan, H. Kang, M. Donahue, D. Claassen, C. Considine (Nashville, USA)

  • Acute Hyperglycemia Without Ketosis Related Movement Disorders: A Case Series

    R. Zouari, M. Akkari, C. Jeridi, MZ. Saeid, F. Nabli, S. Blel, S. Ben Sassi (tunis, Tunisia)

  • ACUTE MOVEMENT DISORDERS: A NEW ASPECT OF SARS-COV2 INFECTION IN CHILDREN

    M. Ben Hafsa (Tunis, Tunisia)

  • Acute polyneuropathy in patients with Parkinson’s disease treated with LCIG

    P. Havránková, R. Jech, M. Baláž, V. čapek, K. Gmitterová, M. Grófik, V. Haň, M. Kaiserová, P. Kaňovský, J. Klempíř, E. Kurča, M. Minár, J. Necpál, I. Rektorová, J. Roth, E. Růžička, M. škorvánek, P. Valkovič (Praha 2, Czech Republic)

  • Acute Stimulation-Induced Ataxia From Thalamic Deep Brain Stimulation

    V. Chandra, Y. Mehkri, A. Desai, C. Hanna, J. Hernandez, J. Yu, J. Frey, J. Wong, J. Hilliard, K. Foote (Gainesville, USA)

  • Addressing pathological alpha-synuclein aggregation using a small molecule strategy

    E. Tsika, N. Ait-Bouziad, N. Dreyfus, C. Vallet, L. Maliqi, L. Aeschbach, S. Pautet, S. Menant, I. Borovko, L. Rey-Bellet, A. Ouared, R. Migliorini, K. Piorkowska, V. Darmency, H. Kroth, S. Poli, A. Pfeifer, M. Kosco-Vilbois (Lausanne, Switzerland)

  • Administration of the mGlu2 positive allosteric modulator BINA as monotherapy improves parkinsonism in the MPTP-lesioned marmoset

    C. Kwan, A. Hamadjida, I. Frouni, S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

  • ADOPTION Study: Status update of a Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson’s Disease

    J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

  • Adrenergic blockers and statins are associated with later age of onset in Parkinson’s disease

    C. Malatt, I. Khatiwala, M. Rangwala, A. Maleki, E. Hogg, E. Tan, M. Tagliati (Los Angeles, USA)

  • ADS024 attenuates striatal dopamine loss and restores movement in animal models of Parkinson’s disease

    L. Chesnel, S. Acton (Concord, USA)

  • Adult-onset Alexander’s disease – New causal mutation in GFAP gene

    T. Goerttler, L. Zanetti, M. Regoni, K. Egger, E. Kellner, C. Deuschl, C. Kleinschnitz, J. Sassone, S. Klebe (Essen, Germany)

  • Adult-onset axial dystonia: a rare condition that can lean on an early combined treatment approach

    P. Mitrotti, G. Vaghi, V. Grillo, C. Susca, R. de Icco, M. Allena, M. Avenali, C. Tassorelli (Pavia, Italy)

  • Adults with slowly progressive dystonia-parkinsonism secondary to manganese accumulation

    R. Dayan, E. Linetzky, H. Mor-Shaked, M. Bauer, C. Muller, D. Arkadir (Jerusalem, Israel)

  • Advance Care Planning and Parkinson’s disease: patient knowledge assessment

    B. Rodrigues, E. Cournean, N. Prakash, D. Costello, K. Badiola, C. Selvadurai (Farmington, USA)

  • Adverse drug reactions to apomorphine: a worldwide pharmacovigilancedatabase analysis

    M. Auffret, C. Le Corre, LM. Scailteux, M. Vérin, E. Polard (Rennes, France)

  • Aerobic glycolysis regulates microglia-mediated neuroinflammation by promoting H3K9 lactylation in Parkinson’s disease

    Q. Qixiong, W. Hengming, W. Danlei, L. Jingyi, Q. Yi, Z. Jingwei, L. Jiangting (wuhan, China)

  • Affected tongue movements in idiopathic REM sleep behavior disorder

    T. Thies, N. Geerts, D. Mücke, A. Seger, M. Barbe, M. Sommerauer (Cologne, Germany)

  • Alien hand syndrome in ischemic stroke: a case-report

    K. Manysheva (Makhachkala, Russian Federation)

  • All that emerge is not Lupus

    M. Spitz, S. de Souza, I. Sodré, B. Panichelli (Rio de Janeiro, Brazil)

  • All that is gold does not glitter: SPG11 mimicking Westphal variant of Huntington’s disease

    A. Baltasar Corral, V. Gómez Mayordomo, A. García Ron, E. López Valdés, R. García-Ramos García (Madrid, Spain)

  • Alpha-synuclein fibril-based mouse model of REM sleep behavior disorder as a prodrome of synucleinopathy

    HS. Yoo, R. Luke, C. Durso, Y. Liang, J. Steltz, D. Chernoff, B. Zhang, KH. Hoxha, B. Dugan, JJ. Fraigne, W. O’Brien, J. Peever, K. Luk (Seoul, Republic of Korea)

  • Alprazolam reduces freezing of gait and improves freezing-related gait measures

    A. Al Jaja, T. Sue, K. Seergobin, J. Grahn, P. Macdonald (London, Canada)

  • Alteration of lysosomal enzymatic activities in blood of patients with schizophrenia

    A. Bezrukova, K. Basharova, M. Nikolaev, E. Palchikova, I. Miliukhina, G. Baydakova, N. Zalutskaya, E. Zakharova, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

  • Alteration of peripheral blood cell profiles in Parkinson’s disease: a retrospective case-control study

    G. Tian, R. Zhou, X. Guo, R. Li (Xi'an, China)

  • Alteration of the fecal microbiota in Turkish patients with idiopathic Parkinson’s disease

    GBY. Babacan-Yildiz, CZK. Kayacan, IK. Karacan, BS. Sumbul, BE. Elibol, OG. Gelisin, OA. Akgul (ISTANBUL, Turkey)

  • Alterations in neuron-derived exosomal cargo in Parkinson Disease

    V. Gorgogietas, IB. Boussaad, F. Borgmann, M. Mittelbronn, R. Krueger (Esch-sur-Alzette, Luxembourg)

  • Alterations of the gustatory circuit underly taste disturbances after lesional tremor therapy with MRgFUS

    V. Purrer, N. Upadhyay, V. Borger, C. Schmeel, H. Boecker, U. Wuellner (Bonn, Germany)

  • Altered Brain Connectivity in Hyperkinetic Movement Disorders: Systematic Review of Resting-State fMRI Studies

    R. Marapin, H. vd Horn, A. vd Stouwe, J. Dalenberg, B. de Jong, M. Tijssen (Groningen, Netherlands)

  • Altered brain dynamics in Parkinson’s disease patients treated by deep brain stimulation

    M. Lamos, M. Bockova, S. Goldemundova, M. Balaz, J. Chrastina, I. Rektor (Brno, Czech Republic)

  • Altered visual network dynamics associated with freezing of gait in Parkinson’s disease

    D. Su, L. Ji, Y. Cui, J. Zhou, T. Wu, J. Stoessl, Y. Liu, T. Feng (Beijing, China)

  • Amantadine Delayed Release/Extended Release Capsules Reduce the Proportion of the Day Spent in “BAD” Time (ON with Troublesome Dyskinesia or OFF): Analysis of Phase 3 Trial Data

    R. Hauser, R. Pahwa, A. Formella (Tampa, USA)

  • Amantadine Is Effective Long-term in Parkinson’s Disease

    S. Park, BS. Jeon (Daejeon, Republic of Korea)

  • Amelioration of Levodopa-induced Dyskinesias using Genetic Silencing of Striatal CaV1.3 in Parkinsonian Rats: Impact of Sex and Advancing Age

    M. Caulfield, F. Manfredsson, J. Stancati, C. Sortwell, S. Boezwinkle, M. Vanderwerp, T. Collier, K. Collier (Grand Rapids, USA)

  • Amygdala-hippocampus damage critically contributes to visual dysfunction in Parkinson disease

    P. Reyero, A. Erramuzpe, A. Murueta-Goyena, A. Jimenez-Marin, M. Acera, S. Teijeira-Portas, B. Tijero, R. Del Pino, T. Fernández-Valle, O. Lucas-Jiménez, N. Ibarretxe-Bilbao, U. Ayala, M. Barrenechea, A. Cabrera-Zubizarreta, J. Cortes, J. Gomez-Esteban, I. Gabilondo (Barakaldo, Spain)

  • An AAV9 encoding human ABCD1 (SBT101) shows functional improvement following spinal cord delivery in a rodent model of adrenomyeloneuropathy

    A. Pujol, A. Bosch, I. Dijkstra, S. Kemp, Y. Jaspers, S. Verdés, S. Fourcade, C. Guilera, M. Leal-Julià, A. Onieva, V. Vasireddy, SW. Clark, D. Anderson, K. Kozarsky (Barcelona, Spain)

  • An accurate yet practical method for DBS battery life prediction

    S. Jinks (Sacramento, USA)

  • AN ATYPICAL ONSET OF PRIMARY FAMILIAL BRAIN CALCIFICATION: A CASE REPORT.

    P. Santurelli, D. Ciprietti, T. Carrer, M. Carecchio (Padova, Italy)

  • An automated AI-based framework for putamen volume measurement in MSA

    M. Papoutsi, J. Weatheritt, M. Reinwald, I. Gidado, R. Joules, H. Kaufmann, I. Qureshi, R. Wolz (London, United Kingdom)

  • An automated data cleaning approach to remove preparation artefacts from brain histology slide images

    V. Giunchiglia, S. Gentleman, R. Nicholas (London, United Kingdom)

  • An Ecologic Study of Aqueous Lead Exposure and Parkinson’s Disease

    G. Schwartz, M. Williamson (Grand Forks, USA)

  • An exploration of tic phenomenology in children with primary tic disorders

    C. Nilles, J. Fletcher, D. Martino, T. Pringsheim (Calgary, Canada)

  • An unusual cause of choreoathetosis: PRES and Goodpasture’s Syndrome

    M. Bonello, M. Cauchi, R. Debono, N. Vella (Pieta, Malta)

  • Analysis of bilateral subthalamic nucleus deep brain stimulation in patients with monogenic forms of Parkinson’s disease: PRKN and LRRK2

    M. Blázquez Estrada, P. Prendes Fernández, E. Suárez Sanmartín, J. Sol Alvarez, C. García Fernández, J. álvarez Carriles, B. Aragoneses, A. Saiz Ayala, E. Santamarta Liébana, M. Alvarez Martínez (Oviedo, Spain)

  • Analysis of Depression and Suicidality Throughout the Course of Huntington Disease Using the Enroll-HD Registry

    S. Reshef, E. Furr Stimming, V. Sung, R. Willock, R. Ribalov, S. Brighton, S. Leo (Parsippany, USA)

  • Analysis of somatosensory temporal discrimination in essential tremor treated with HIFU VIM thalamotomy: tremoric and lesional effects on the STDT

    CM. Ordás, F. Alonso-Frech, R. Martínez-Fernández, M. Del álamo, JA. Obeso (Móstoles, Spain)

  • Analysis of tremor during grasp using ultrasound imaging.

    A. Iyer, X. Xue, D. Roque, N. Sharma (Raleigh, USA)

  • Analyzing early states of HD progression using a machine learning driven approach

    E. Eyigoz, S. Sathe, J. Warner, S. Dey, T. Li, P. Rojas, C. Sampaio, J. Hu (Yorktown Heights, USA)

  • Analyzing gait videos to identify and evaluate spinocerebellar ataxia types 1 and 3

    P. Yang, M. Hasan, W. Rahman, M. Islam, T. Olubajo, J. Thaker, A. Abdelkader, E. Hoque, T. Ashizawa (Rochester, USA)

  • Analyzing the metabolic function of DJ-1 in the pathogenesis of Parkinson`s disease (PD) and Glioblastoma multiforme (GBM)

    P. Mencke (Esch-sur-Alzette, Luxembourg)

  • Anatomical Substrates for Motor Subcomponents of Bradykinesia in Parkinson’s Disease after Subthalamic Nucleus Deep Brain Simulation

    MJ. Kim, Y. Shi, Y. Salimpour, WS. Anderson, K. Mills (Baltimore, USA)

  • Anosognosia in HD: Comparison of Self-report and Caregiver Ratings with Objective Performance Measures

    SB. Hughes, A. Smirnova, A. Hall, C. Snell, B. Wright, PE. Gilbert, J. Corey-Bloom (San Diego, USA)

  • Anthropometric Changes in Parkinson’s Disease: Canadian Longitudinal Study on Aging

    S. Zolfaghari, A. Pelletier, R. Postuma (Montreal, Canada)

  • Anti-IgLON5 mediated autoimmune encephalitis presenting with hemichorea

    A. Grossauer, A. Hussl, P. Mahlknecht, A. Heidbreder, K. Seppi, B. Heim (Innsbruck, Austria)

  • Anti-Ma2 Antibody Paraneoplastic Cerebellar Degeneration Associated with Renal Cell Carcinoma: A Case Report.

    K. Zahra, N. Ahmed, D. Sivakumar, E. Urrea-Mendoza, V. Veerappan (Greenville, USA)

  • Anti-α-synuclein antibody 5G4 differentiates idiopathic REM Sleep Behavior Disorder patients from healthy controls in skin biopsies

    S. Toth, K. Kulcsarova, E. Feketeova, J. Ventosa, M. Maretta, A. Kunova, M. Bekeova, P. Christova, J. Baloghova, E. Mechírová, Z. Gdovinova, M. Skorvanek (Kosice, Slovakia)

  • Antidyskinetic Effects of CaV1.3 Calcium Channel Gene Silencing in Aged Male and Female Parkinsonian Macaques

    K. Steece-Collier, F. Manfredsson, S. Muller, M. Caulfield, M. Vander Werp, J. Stancati, Y. Chu, I. Sandoval, T. Collier, J. Kordower (Grand Rapids, USA)

  • Antipsychotic use in Parkinson’s disease: a single center retrospective chart review

    S. Brooker, C. Yeh, D. Larson (Chicago, USA)

  • Apathy and Volume of Tissue Activated (VTA) following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Cohort

    T. Stiep, A. Ramirez-Zamora, J. Wong, A. Tröster, R. Jain, L. Chen, M. Malek, M. Okun (Gainesville, USA)

  • Apathy in Parkinson’s disease: serum biochemical markers and clinical features

    LT. Li, Y. Qu, HL. Gao, YJ. Xiong, Z. Min, ZJ. Mao, JY. Li, QX. Qin, DL. Wang, JW. Zhao, Z. Xue (Wuhan, China)

  • APEG-PCL Nanoparticles Containing Rifampicin Target Dopaminergic Neurons to reduce α-synuclein aggregation

    D. Lin, K. Huang (Shenzhen, China)

  • APOE effect on Progressive Supranuclear Palsy phenotypes

    Y. Abida, I. Kacem, S. Mrabet, A. Gharbi, A. Souissi, A. Gargouri, A. Nasri, R. Gouider (Mannouba, Tunisia)

  • Apomorphine Hydrochloride Injection Treatment Initiations in the Presence and Absence of an Antiemetic in People with Parkinson Disease

    C. Happel, M. Grall, B. Lujan, A. Formella (Rockville, USA)

  • Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Incremental Motor Improvement Observed with Increasing Doses

    S. Isaacson, I. Zhang, E. Pappert, A. Bowling (Boca Raton, USA)

  • Apomorphine sublingual film patient-reported motor status response at home throughout the day

    J. Obeso, K. Chaudhuri, R. Hauser, G. Jones, G. Castilla-Fernández, D. Magalhães (Madrid, Spain)

  • Apomorphine Sublingual Film Titrated at Home in Patients With Parkinson’s Disease and OFF Episodes: Results From an Open-Label, Randomized, Crossover Study

    J. Kassubek, F. Stocchi, E. Balaguer, S. Isaacson, I. Zhang, A. Bowling, S. Wu, E. Pappert (Ulm, Germany)

  • Apomorphine Sublingual Film Versus Subcutaneous Apomorphine in the Treatment of OFF Episodes in Parkinson’s Disease: Results From an Assessment of Patient Satisfaction

    J. Schwarz, C. Carroll, G. Ebersbach, J. Kulisevsky, A. Tessitore, I. Zhang, A. Bowling, S. Wu, E. Pappert, A. Thach (Oberbayern, Germany)

  • Application of Goal Attainment Scale as a patient-centered assessment for cervical dystonia

    P. Wongwan, P. Panyakaew, R. Bhidayasiri (Bangkok, Thailand)

  • Aquatic Physical Therapy: Effects on Functional Mobility in people with Parkinson’s Disease

    J. Siega, T. Christinelli, G. Leveck, A. Silva, V. Israel (CURITIBA, Brazil)

  • Are Subjective Cognitive Complaints a predictor of future cognitive decline in Parkinson´s Disease? – A longitudinal study

    M. Magriço, B. Meira, M. Fernandes, M. Saraiva, M. Salavisa, C. Borbinha, J. Maro, F. Ladeira, R. Barbosa, P. Bugalho (Lisboa, Portugal)

  • Aromatic L-amino acid decarboxylase deficiency: A rare disease case report and literature review

    P. Bacus, R. Sauer, T. Kini, Z. Guduru, K. Jones (Lexington, USA)

  • Artificial Intelligence based detection of Parkinson’s disease in Magnetic Resonance Imaging brain scans

    M. Courtman, M. Thurston, L. Mcgavin, C. Carroll, L. Sun, E. Ifeachor, S. Mullin (Plymouth, United Kingdom)

  • Assessment of cognitive functions and gait in PD and ET patients with pharmacoresistant tremor treated with Gamma Knife thalamotomy.

    M. Figura, L. Milanowski, K. Sadowski, A. Korn, A. Ziobro, D. Koziorowski (Warsaw, Poland)

  • Assessment of microstructural changes associated with levodopa-induced dyskinesia in hemiparkinsonian rodents

    M. Bergamino, A. Fuentes, D. Marmion, I. Sandoval, C. Bishop, F. Manfredsson, A. Stokes (Phoenix, USA)

  • Assessment of mood symptoms and influence on disease in cervical dystonia

    S. Rafee, S. O'Riordan, M. Hutchinson (Dublin, Ireland)

  • Assessment of non-motor symptoms of Parkinson’s disease in the long-term follow-up after the cell therapy

    V. Chyzhyk, A. Boika, V. Ponomarev (Minsk, Belarus)

  • Assessment of novel diffusion MRI metrics of cortical microstructure in the genetic continuum of Parkinson’s disease

    M. Torso, D. Tzaferou, M. Valotti, J. Hardwidge, I. Hardingham, Q. Guo, R. Comley, S. Chance, G. Ridgway (Oxford, United Kingdom)

  • Assessment of the long-term effects of STN-DBS on axial symptoms in PD patients through a standardized clinical-instrumental approach

    F. Cavallieri, I. Campanini, A. Gessani, V. Fioravanti, B. Damiano, S. Scaltriti, E. Bardi, M. Corni, F. Antonelli, V. Rispoli, G. Di Rauso, F. Cavalleri, M. Molinari, S. Contardi, E. Menozzi, S. Meletti, G. Biagini, E. Moro, C. Budriesi, A. Merlo, F. Valzania (Reggio Emilia, Italy)

  • Association between dihydropyridines and dementia conversion in Parkinson’s disease

    JH. Jung, SH. Jeong, SJ. Chung, HS. Yoo, K. Baik, BS. Ye, SJ. Kim, YH. Sohn, PH. Lee (Busan, Republic of Korea)

  • Association between income and hospital length of stay in Parkinson Disease: a nationwide cross-sectional analysis

    P. Gros, D. Di Luca, C. Marras, A. Lang (Toronto, Canada)

  • Association between longitudinal degeneration of the cholinergic basal forebrain and cognition-relevant cortical areas in early-stage PD

    M. Labrador-Espinosa, J. Silva-Rodríguez, P. Mir, M. Grothe (Sevilla, Spain)

  • Association Between Over-the-Counter Dietary Supplements and Parkinson’s Disease Symptom Severity Over Time

    L. Mischley, J. Farahnik (Kenmore, USA)

  • Association between sleep apnea and prognosis in patients with multiple system atrophy

    S. Jo, S. Lee, J. Lee, SA. Lee, SJ. Chung (Seoul, Republic of Korea)

  • Association between thyroid dysfunction and severity of depression in de novo patients with Parkinson’s disease

    I. Sarac, H. Sarac, N. Henigsberg, F. Borovecki, L. Bagaric Krakan, I. Ivek, M. Iveta, T. Sukobljevic, Z. Kresic (Zagreb, Croatia)

  • Association of a new pathogenic variant of LRRK2 with modifying lysosomal genes in a family with Parkinson’s disease

    L. Vela-Desojo, M. Osuna-Lopez, C. Guerrero, A. Pascual, F. Palau, J. Hoenicka (Alcorcón, Spain)

  • Association of accelerometer-derived sleep and idiopathic dystonia: A UK Biobank cohort study

    G. Bailey, M. Wadon, S. Komarzynski, C. Matthews, EH. Davies, K. Peall (Cardiff, United Kingdom)

  • Association of creaky voice with motor severity in Parkinson’s disease using an automated algorithm.

    V. Wei, C. Manxhari, E. Morrison, K. Smith (Worcester, USA)

  • Association of glucocerebrosidase genotype and disease progression in early Parkinson’s disease over the course of 80 weeks

    H. Frequin, B. Ferwerda, C. Verschuur, S. Suwijn, J. Dijk, R. de Bie (Amsterdam, Netherlands)

  • Association of type 2 diabetes and dementia in elderly patients with Parkinson’s disease: a population-based study in Korea

    S. Lee, J. Lee, D. Kim, H. Kim, M. Choi, S. Jo, S. Chung (Seoul, Republic of Korea)

  • Associations between stimulation-induced gamma entrainment and motor signs of Parkinson’s Disease

    M. Olaru, A. Hahn, J. Anso, C. Oehrn, J. Sermon, R. Bogacz, T. Denison, B. Duchet, S. Little, P. Starr (San Francisco, USA)

  • ASYMMETRIC EARLY-ONSET PARKINSONISM DUE TO PSEN1 MUTATION

    E. Luque-Buzo, J. Pérez Sáchez, M. Gonzalez-Sanchez, A. Contreras-Chicote, S. Secades, B. Casa-Fages, F. Grandas (Madrid, Spain)

  • Asymmetric midbrain atrophy in a patient with progranulin-related FTLD

    A. Ameri, A. Mahajan, M. Rosenbaum, L. Verhagen Metman (Chicago, USA)

  • Asymmetry of Motor and Non-motor Signs in Parkinson’s Disease: An Exploratory Clinical Case-control Study

    F. Hansen, N. Okkels, P. Borghammer (Aarhus N, Denmark)

  • At-home prolonged adaptive deep brain stimulation improves symptoms and reduces side effects in Parkinson’s disease

    C. Oehrn, S. Cernera, L. Hammer, M. Shcherbakova, A. Hahn, R. Gilron, C. Smyth, R. Wilt, S. Little, P. Starr (SAN FRANCISCO, USA)

  • Attending to Compensatory Strategies during Prolonged Walking in Parkinson Disease: A Pilot Study

    G. Yogev-Seligmann, M. Kafri (Haifa, Israel)

  • Atypical parkinsonism presenting in late 60s in an individual with GCH1 mutation

    P. Barbosa, MG. Ghilardi, AC. Campos, F. Curado, P. Bauer, E. Fonoff (Sao Paulo, Brazil)

  • Atypical parkinsonism presenting with isolated gaze palsy: implications for prognosis

    D. Damas, I. Carvalho, A. Jorge, I. Cunha, A. Morgadinho, J. Lemos, F. Moreira (Coimbra, Portugal)

  • Atypical parkinsonism related to a rare variant in the PLA2G6 gene

    L. Rabaneda-Lombarte, K. Beyer, L. Ispierto, D. Vilas-Rolan (Badalona, Spain)

  • Audit of dysphagia care provided to Parkinson’s patients during acute hospital admission

    M. Khwaja, G. Desai, J. Murphy, A. Chatterjee (Reading, United Kingdom)

  • Automated error detection when applying the protocol for the monitoring of motor function in patients with Parkinson’s disease using smartwatches.

    L. Sigcha, JM. Cermeño, MB. Domínguez, I. Pavón, JC. Matínez, JM. López, G. de Arcas (Madrid, Spain)

  • Automated quantification of facial bradykinesia through video in de-novo Parkinson’s disease

    M. Novotný, H. Růžičková, E. Růžička, P. Dušek, J. Rusz, T. Tykalová (Prague 6, Czech Republic)

  • Automated scoring of REM sleep without atonia using the open-source software RBDtector

    CEJ. Doppler, A. Röthenbacher, N. Okkels, N. Willemsen, N. Sembowski, AD. Seger, M. Lindner, C. Brune, S. Bialonski, P. Borghammer, GR. Fink, M. Schober, M. Sommerauer (Köln, Germany)

  • Automatic Speech Recognition for speech therapy in a Parkinson’s disease patient

    A. Nuzzi (Bari, Italy)

  • Autonomic dysfunction and its correlation witn synucleinopathy: an immunohistological study in Tunisian patients with parkinson disease

    N. Ben Ali, L. Ali, S. Fezai, H. Jamoussi, S. Fray, M. Ben Mahmoud, M. Fredj (Tunis, Tunisia)

  • Autonomic dysfunction in p.A53T SNCA PD vs GBA PD and idiopathic PD : A study in a Greek population.

    AM. Simitsi, P. Kokotis, C. Koros, C. Bougea, N. Papagiannakis, R. Antonelou, I. Pachi, D. Papadimitrioy, M. Stamelou, L. Stefanis (ATHENS, Greece)

  • Autonomic Nervous System Dysfunction in idiopathic REM sleep behaviour disorder

    Y. Shao, T. Wijratne (Melbourne, Australia)

  • Availability and accessibility of medicines for patients with Parkinson’s disease in Kyrgyzstan

    C. Shambetova (Bishkek, Kyrgyzstan)

  • Awake Bruxism, a case series of an underrecognized disorder

    I. Trigo, B. Solano Vila, D. Domínguez (Girona, Spain)

  • Awake versus Asleep Deep Brain Stimulation Lead Placement: Real-World Outcomes with Directional DBS Systems

    J. Vesper, G. Deuschl, L. Chen, R. Jain (Düsseldorf, Germany)

  • Axial hypotonia – A pointer towards NBIA – PLA2G6-Associated Neurodegeneration

    VM. Mathur, DK. Khandelwal, DS. Sharma, AG. Gupta (Mumbai, India)

Jump to:  View All • [a] b c d e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
        • Help & Support
        • About Us
        • Cookies & Privacy
        • Wiley Job Network
        • Terms & Conditions
        • Advertisers & Agents
        Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
        Wiley